Related Experiment Video
Updated: Jul 11, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Mycophenolate mofetil in lupus glomerulonephritis: effectiveness and tolerability
Luca Iaccarino1, Silvia Arienti, Mariaelisa Rampudda
1Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.
Mycophenolate mofetil (MMF) effectively treats lupus nephritis (LN) in patients resistant to other therapies. This immunosuppressive drug offers a well-tolerated alternative for managing this severe autoimmune condition.
Area of Science:
- Immunology
- Nephrology
- Rheumatology
Background:
- Mycophenolate mofetil (MMF) is an immunosuppressant used in organ transplantation to prevent rejection.
- Systemic lupus erythematosus (SLE) is an autoimmune disease with potential multi-organ involvement.
- Lupus glomerulonephritis (GLN) is a severe SLE manifestation impacting long-term prognosis.
Purpose of the Study:
- To evaluate Mycophenolate mofetil (MMF) as an alternative treatment for lupus glomerulonephritis (GLN).
- To assess the efficacy and tolerability of MMF in patients with refractory lupus GLN.
Main Methods:
- Review of studies investigating MMF in lupus GLN treatment.
- Comparison of MMF efficacy and safety against traditional immunosuppressive agents.
Main Results:
- MMF demonstrates effectiveness in reducing acute rejection episodes in transplant recipients.
- MMF selectively suppresses T and B lymphocyte proliferation.
- MMF has emerged as a viable alternative for lupus GLN, particularly in refractory cases.
Conclusions:
- Mycophenolate mofetil (MMF) is a highly effective and generally well-tolerated treatment option for lupus glomerulonephritis (GLN).
- MMF offers a promising therapeutic strategy for patients with SLE-related kidney disease who have not responded to other treatments.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Nephrotic Syndrome II : Assessment and Medical Management
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Drug Elimination by Renal Route: Glomerular Filtration
